Recent investigations have centered on the intersection of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and dopaminergic signaling. While GCGR activators are commonly employed for treating type 2 diabetes, their unexpected impacts on reinforcement circuits, specifically influenced by dopamine pathways, are attracting… Read More